🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Steven Cohen’s SYRE Holdings & Trades

First Buy
Q4 2025
Duration Held
3 Quarters
Largest Add
Q4 2025
+662,351 Shares
Current Position
356,923 Shares
$31.78 M Value

Steven Cohen's SYRE Position Overview

Steven Cohen (via Point72 Asset Management, L.P.) currently holds 356,923 shares of Spyre Therapeutics, Inc. (SYRE) worth $31.78 M, representing 0.04% of the portfolio. First purchased in 2025-Q4, this short-term holding has been held for 3 quarters.

Based on 13F filings, Steven Cohen has maintained this position in SYRE for several quarters, showing initial confidence in the investment. Largest addition occurred in Q3 2026, adding 356,923 shares. Largest reduction occurred in Q1 2026, reducing 662,351 shares.

Analysis based on 13F filings available since 2013 Q2

Steven Cohen's Spyre Therapeutics (SYRE) Holding Value Over Time

Track share changes against reported price movement

Quarterly Spyre Therapeutics (SYRE) Trades by Steven Cohen

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q3 2026 +356,923 New Buy 356,923 $89.03
Q1 2026 -662,351 Sold Out 0 $0.00
Q4 2025 +662,351 New Buy 662,351 $32.76

Steven Cohen's Spyre Therapeutics Investment FAQs

Steven Cohen first purchased Spyre Therapeutics, Inc. (SYRE) in Q4 2025, acquiring 662,351 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Steven Cohen has held Spyre Therapeutics, Inc. (SYRE) for 3 quarters since Q4 2025.

Steven Cohen's largest addition to Spyre Therapeutics, Inc. (SYRE) was in Q4 2025, adding 662,351 shares worth $21.7 M.

According to the latest 13F filing for Q3 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 356,923 shares of Spyre Therapeutics, Inc. (SYRE), valued at approximately $31.78 M.

As of the Q3 2026 filing, Spyre Therapeutics, Inc. (SYRE) represents approximately 0.04% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.

Steven Cohen's peak holding in Spyre Therapeutics, Inc. (SYRE) was 662,351 shares, as reported at the end of Q4 2025.